As the only GLP-1RAs identical to human GLP-1 (7–36), beinaglutide is expected to provide a new treatment option for the prevention and management of overweight/obesity and become the first novel GLP-1RA approved for weight management indications in China. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.